<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>02876nam a2200289Ia 4500</leader>
  <controlfield tag="008">230719s2016    xx            000 0 und d</controlfield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="a">9780128042175</subfield>
  </datafield>
  <datafield tag="050" ind1=" " ind2=" ">
    <subfield code="a">R 853.C55 B76 2016</subfield>
  </datafield>
  <datafield tag="099" ind1=" " ind2=" ">
    <subfield code="a">15835</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Brody, Tom</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Clinical trials : </subfield>
    <subfield code="b">study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines/</subfield>
    <subfield code="c">Brody, Tom.</subfield>
  </datafield>
  <datafield tag="250" ind1=" " ind2=" ">
    <subfield code="a">Second edition.</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2=" ">
    <subfield code="a">Amsterdam, Netherlands :</subfield>
    <subfield code="b"></subfield>
    <subfield code="b">Elsevier/Academic Press, </subfield>
    <subfield code="c">2016.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">xxxii, 863 pages : </subfield>
    <subfield code="b">some illustrations ; </subfield>
    <subfield code="c">24 cm.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Includes bibliographical references and index.</subfield>
  </datafield>
  <datafield tag="505" ind1=" " ind2=" ">
    <subfield code="a">Origins of drugs -- Clinical trial design -- Run-in period -- Inclusion/exclusion criteria, stratification, and subgroups, part I -- Inclusion/exclusion criteria, stratification, and subgroups, part II -- Blinding, randomization, and allocation -- Placebo arm as part of clinical trial design -- Intent-to-treat analysis versus per protocol analysis -- Biostatistics, part I -- Biostatistics, part II -- Introduction to endpoints -- Oncology endpoints : overall survival and progression-free survival -- Oncology endpoints : time to progression -- Oncology endpoint : disease-free survival -- Oncology endpoint : time to distant metastasis -- Neoadjuvant therapy versus adjuvant therapy -- Hematological cancers -- Biomarkers -- Endpoints for immune diseases -- Endpoints for infections -- Health-related quality of life tools --oncology -- Health-related quality-of-life tools --immune disorders -- Health-related quality-of-life tools --infections -- Drug safety -- Mechanism of action of diseases and drugs, part I -- Mechanism of action, part II (cancer) -- Mechanism of action, part III (immune disorders) -- Mechanisms of action, part IV (infections) -- Consent forms -- Package inserts -- Warning letters -- Regulatory approval -- Patents.</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">This text offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial design, the 2nd edition of Clinical Trials is a must-have resource for early and mid-career researchers and clinicians who design and conduct clinical trials.</subfield>
  </datafield>
  <datafield tag="521" ind1=" " ind2=" ">
    <subfield code="a">MED</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">MEDICINE</subfield>
  </datafield>
  <datafield tag="591" ind1=" " ind2=" ">
    <subfield code="a">/Brody, Tom.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">Clinical trials</subfield>
    <subfield code="x">Design.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">Clinical trials as topic.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">Drug approval.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">Drugs</subfield>
    <subfield code="x">Testing.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">Research design.</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="2">lcc</subfield>
    <subfield code="h">R</subfield>
    <subfield code="c">MED</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">87258</subfield>
    <subfield code="d">87258</subfield>
  </datafield>
</record>
